Sichuan University clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 4 with minor changes only.

1. Minor

   4 trials marked Unknown by the registry's verification sweep

   1. Minor

      Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for…Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Sichuan University·Phase 2· NCT06603402· Registry history of NCT06603402 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   2. Minor

      MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

      Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting

      Sichuan University·Phase 2· NCT06075225· Registry history of NCT06075225 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   3. Minor

      Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

      Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting

      Sichuan University·Phase 2· NCT06075238· Registry history of NCT06075238 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   4. Minor

      Aromatherapy for First Dental Visit Patients

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

      Sichuan University·Not applicable· NCT06598904· Registry history of NCT06598904 on ClinicalTrials.gov (opens the registry)

      Changed Oct 4, 2026

   Registry verification sweep

   Changed Oct 4, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.